Major Developments

ELATE HOLDINGS (00076) plans to acquire up to 69% equity in AOMI Corporation for a maximum of HK$754 million. BRII-B (02137) announced the launch of the BRiSC™ siRNA drug research and development platform. CSPC PHARMA (01093): SYS 6088 injection (trispecific antibody) has received clinical trial approval in China. BAIYUNSHAN PH (00874): Amikacin sulfate injection (2ml:0.2g) (200,000 units) has passed the generic drug quality and efficacy consistency evaluation. YUNJI-NEW (02506) has entered into a cooperation framework agreement with Shanghai Ruici Medical to promote AI medical large models and explore commercialized health management solutions.

Operating Performance

YUNJI-NEW (02670) maintained steady growth in robot operations scale in the first nine months, with products cumulatively covering over 45,000 hotels. BRII-B (02162): Kangyueda® generated total revenue of approximately RMB 660 million in the first three quarters, representing a year-on-year increase of approximately 227%. CHALIECO (02068) signed new contracts totaling RMB 21.788 billion in the first three quarters, a year-on-year increase of 1.53%. GANFENG LITHIUM (01772) achieved net profit attributable to shareholders of approximately RMB 5.012 billion in the first three quarters, a year-on-year increase of 19,540.50%. MARKETINGFORCE (02556) recorded a year-on-year revenue growth of approximately 114% in its AI application business in the first three quarters. PACIFIC BASIN (02343) maintained strong spot market average daily charter rates for Handysize and Supramax dry bulk carriers in the third quarter. ZHAOJIN MINING (01818) released its third quarter results with operating revenue of RMB 13.51 billion, a year-on-year increase of 8.69%.